3+、CD4+、CD4+/CD8+均顯著高于對(duì)照組(P<0.05)。研究組治療后D-dimer、APACHEⅡ評(píng)分均顯著低于對(duì)照組水平(P<0.05);研究組7 d內(nèi)MODS發(fā)生率(13.3% vs 20.0%)與病死率(10.7% vs 13.3%)低于對(duì)照組,但差異均無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 烏司他丁治療重癥膿毒癥基礎(chǔ)上聯(lián)合使用血必凈注射液能進(jìn)一步抑制炎癥反應(yīng),調(diào)節(jié)細(xì)胞免疫功能,減輕高凝狀態(tài)。;Objective To observe the influences of Xuebijing injection combined with UTI on variations of serum factor, T cell subsets and D-dimer for severe sepsis patients. Methods 150 severe sepsis patients from January 2014 to March 2016 were selected and randomly divided into study group and control group, each with 75 cases, based on conventional therapy control group added with UTI injection for 7d,observation group jointly added with Xuebijing injection, variations of inflammatory factor, T cell subsets and D - dimer levels before and 7d after treatment were noted,and MODS incidence and 7 d mortality ratio of the two groups were compared. Results The study group after treatment with TNF-α, IL-6, CRP, PCT were significantly lower than the control group (P<0.05). CD3+, CD4+, CD4+/CD8+ of study group after treatment were significantly higher than the control group (P<0.05). D-dimer and APACHEⅡ score of study group after treatment were significantly lower than the control group (P<0.05). MODS incidence rate (13.3% vs.20.0%) and mortality ratio (10.7% vs.13.3%) of study group within 7d were both lower than the control group, but the difference were not significant. Conclusion Based on UTI treatment for severe sepsis, Xuebijing injection added can further suppress inflammatory response, regulate cell immune function, alleviate the hypercoagulable state."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁(yè) > 過(guò)刊瀏覽>2018年第41卷第6期 >2018,41(6):1077-1081. DOI:10.7501/j.issn.1674-6376.2018.06.025
上一篇 | 下一篇

血必凈注射液聯(lián)合烏司他丁對(duì)膿毒癥患者血清因子、T細(xì)胞亞群及D-二聚體的影響

Xuebijing injection combined with ulinastatin in the treatment of severe sepsis patients and its influence on serum factors, T cell subgroup and D-dimer

發(fā)布日期:2018-06-05
您是第位訪問(wèn)者
藥物評(píng)價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號(hào) 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào):(津)-非經(jīng)營(yíng)性-2015-0031